BioMark Diagnostics Inc.
- Home
- Companies
- BioMark Diagnostics Inc.
- Products
- BioMark - Liquid Biopsy Metabolic Panel ...
BioMark - Liquid Biopsy Metabolic Panel Assays
BioMark has invested in and developed a new high powered liquid biopsy metabolic panel assay. The new metabolic assay is instrumental for early stage diagnosis of lung cancer.
Most popular related searches
metabolic panel
liquid biopsy
biopsy panel
lung cancer
neck cancer
gene expression
breast cancer
clinical trial
human cancer
biopsy
The liquid biopsy metabolic panel has demonstrated superior clinical detections. The capabilities include early stage I and II Lung Cancers using urine and plasma.
This is a major breakthrough in Lung Cancer diagnostics.
The discovery positions BioMark for high risk lung cancer screening. This market currently uses low dose CT scans (LDCT). Machine learning is being used by BioMark in the analysis of the assay.
Cancer Research
Liquid Biopsy Metabolic Panels Being Developed for Other Cancers
- Glioblastoma (GBM)
- Breast Cancer
- Head & Neck Cancer
Application:
- Screening for high risk group
- Precision medicine
- Assess high risk relapse population cohort
- Assess malignancy
Clinical Trials:
Spermidine/spermine N-acetyltransferase 1 (SSAT 1) Gene Expression in Human Cancer
Principal Investigator: Dr. Andrew Maksymiuk, MD, Cancer Care Manitoba
Status: Open
Spermidine/spermine N-acetyltransferase 1 (SSAT1) Gene Expression and Identification of High-Performance Metabolites in Human Cancer (Amended)
Principal Investigator: Dr. Andrew Maksymiuk, MD, Cancer Care Manitoba
Co-Investigator: Dr. Daniel S. Sitar, Ph.D, University of Manitoba
Co-Investigator: Dr. Paramjit Tappia, Ph.D, Asper Clinical Research Institute
Status: Open
Glioblastoma (GBM)
- CancerCare Manitoba ethics approval obtained for the protocol
- Patients to be recruited newly diagnosed and treated
- Utilize both SSAT1 and new panels
- Expand clinical trial sites in N. America
Breast Cancer
- Identified and validated several putative markers
- Expanding trial samples
- Incorporate other clinical and imaging data
Head / Neck Cancer
- In discussion with a major European centre to develop a comprehensive Omics panel of markers for high relapse cancer cohort
- Modify protocol and potentially extend trial to additional North American sites after Health Canada and ethics approvals are granted.